Clinical trial / 2014
A probiotic drink with Lactobacillus casei DN 114001 was linked to lower AAD incidence and confirmed preventive effects in a pilot trial.
In an observational study of 258 patients with infections receiving antibiotics, 107 were offered a probiotic drink containing Lactobacillus casei DN 114001 b.i.d. AAD incidence was 6.5% in the probiotic group versus 28.4% in controls, and duration was 1.7 ± 1.1 versus 3.1 ± 2.1 days. A second randomized controlled pilot study of 60 patients directly compared two probiotic drinks and confirmed the preventive effect for L. casei DN 114001, but found no advantage for a drink containing Lactobacillus casei Shirota.
- Study type
- Observational study followed by a randomized controlled pilot trial
- Who was studied
- 258 patients with infections in an observational study; 60 patients in a randomized pilot trial
- What was measured
- Incidence and duration of antibiotic-associated diarrhea (AAD), and cost-efficiency
THE PAPER
Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea.
Dietrich CG, Kottmann T, Alavi M. World J Gastroenterol, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.